Globe NewsWire News Distribution Service

Details

Written by Globe NewsWire Press Releases

Category: Globe NewsWire News Distribution Service

Published: 12 June 2024

Created: 12 June 2024

Last Updated: 12 June 2024

SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that the Board of…

Posted: 2024-06-12 22:03:00

Get Full News Story On GlobeNewsWire Press Release Service

Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

• Prev
• Next

Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Newscast

Boehringer Ingelheim Commits to Veeva Vault CRM

Thu, 14 Nov 2024 07:03:00 GMT Top biopharma company selects the next generation of CRM for life sciences as its commercial foundation for future expansion and launches BARCELONA, Spain, Nov. 14, 2024 /PRNewswire/ -- Veeva Systems ...

Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year

Tue, 12 Nov 2024 05:48:00 GMT CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in ...

aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update

Thu, 07 Nov 2024 08:01:00 GMT aTyr is currently investigating efzofitimod in the global Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis, a major form of ILD, and in the Phase 2 EFZO-CONNECT™ study ... www.atyrpharma ...

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Fri, 01 Nov 2024 05:19:00 GMT Nov. 01, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ...

LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine

Fri, 25 Oct 2024 05:30:00 GMT These statements are based on various assumptions, whether identified in this press release, and on the current expectations of LakeShore Biopharma's management and are not predictions of actual ...